Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 1, 2013, Pages 56-61

  Milan Segovia R C ^a,b   Dominguez Ramirez A M ^a   Jung Cook, H ^c   Magana Aquino M ^d   Vigna Perez M ^b   Brundage, R C ^e   Romano Moreno, S ^b  

^a UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

antituberculosis drug; non linear mixed effect modelling; NONMEM; population pharmacokinetics; rifampicin

Indexed keywords

RIFAMPICIN; RIFATER;

ADDICTION; ADULT; AGE; ARTICLE; BODY HEIGHT; BODY MASS; BODY SURFACE; BODY WEIGHT; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSPECTIVE STUDY; TUBERCULOSIS; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; MALE; MEXICO; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROSPECTIVE STUDIES; RIFAMPIN; SEX FACTORS; TISSUE DISTRIBUTION; TUBERCULOSIS; YOUNG ADULT;

EID: 84871990412     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12016     Document Type: Article

References (36)

1. Secretaría de Salud, Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. Programas Preventivos. Alianza comunitaria SOLUCIÓN TB. Mexico City: CENAVE, Boletín Informativo [on line] 2010. Available at: http://www.cenave.gob.mx/tuberculosis/WEB/ descargas1/2010/BTB-Feb.pdf (accessed 20 July 2010).
2. Peloquin CA,. Serum concentrations of the antimycobacterial drugs. Chest, 1998; 113: 1154-1155. (Pubitemid 28223794)
3. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW,. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother, 2009; 53: 2974-2981.
4. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P,. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother, 2006; 50: 1170-1177.
5. Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM,. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest, 2001; 120: 1520-1524. (Pubitemid 33078467)
6. Pargal A, Rani S,. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int J Tuberc Lung Dis, 2001; 5: 70-79. (Pubitemid 32401879)
7. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE,. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother, 2007; 51: 2546-2551. (Pubitemid 47047335)
8. Prakash J, Velpandian T, Pande JN, Gupta SK,. Serum rifampicin levels in patients with tuberculosis: effect of P-glycoprotein and CYP3A4 blockers on its absorption. Clin Drug Investig, 2003; 23: 463-472. (Pubitemid 36920518)
9. van Crevel R, Alisjahbana B, de Lange WC, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis, 2002; 6: 497-502. (Pubitemid 34601866)
10. Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother, 2008; 52: 2138-2148. (Pubitemid 351758551)
11. Le Guellec C, Gaudet ML, Lamanetre S, Breteau M,. Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. Ther Drug Monit, 1997; 19: 669-674. (Pubitemid 28046994)
12. Jonsson EN,. Xpose: an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed, 1999; 58: 51-64. (Pubitemid 29049052)
13. Milán-Segovia RC, Domínguez-Ramírez AM, Jung-Cook H, et al. Romano-Moreno Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis, 2010; 14: 1454-1460.
14. Sheiner LB, Beal SL,. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm, 1981; 9: 631-651.
15. Grasela TH,. Population pharmacokinetics: application to clinical trials. In:, Smith RB, Kroboth PD, Juhl RP, eds. Pharmacokinetics and Pharmacodynamics. Research Design and Analysis. Cincinnati: Harvey Witney Books, 85-103, 1986.
16. Lee PI,. Design and power of a population pharmacokinetic study. Pharm Res, 2001; 18: 75-82. (Pubitemid 32299625)
17. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW,. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother, 1997; 41: 2670-2679. (Pubitemid 27524738)
18. Agrawal S, Panchagnula R,. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos, 2005; 26: 321-334. (Pubitemid 41684538)
19. Becker C, Dressman JB, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. J Pharm Sci, 2009; 98: 2252-2267.
20. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK,. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig, 1999; 104: 147-153.
21. Budha NR, Lee RE, Meibohm B,. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Curr Med Chem, 2008; 15: 809-825. (Pubitemid 351516798)
22. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis, 2006; 43: 848-854. (Pubitemid 44435511)
23. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother, 2004; 48: 4473-4475. (Pubitemid 39434921)
24. Schwartz JB,. The influence of sex on pharmacokinetics. Clin Pharmacokinet, 2003; 42: 107-121. (Pubitemid 36188552)
25. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF,. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol, 2004; 44: 499-523. (Pubitemid 38263851)
26. Anderson GD,. Gender differences in pharmacological response. Int Rev Neurobiol, 2008; 83: 1-10.
27. Hu TM, Hayton WL,. Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci, 2001; 3: 1-14.
28. Berdel W, Edler L, Jaehde U, et al. SOP 14. Population pharmacokinetic analysis. Standard operating procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research-EWIV. Onkologie, 2003; 26 (suppl 6), 60-66.
29. Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl, 2002; 8: 233-240. (Pubitemid 34257205)
30. Meibohm B, Beierle I, Derendorf H,. How important are gender differences in pharmacokinetics? Clin Pharmacokinet, 2002; 41: 329-342. (Pubitemid 34713088)
31. Soldin OP, Mattison DR,. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet, 2009; 48: 143-157.
32. Tirona RG, Leake BF, Wolkoff AW, Kim RB,. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther, 2003; 304: 223-228. (Pubitemid 36008932)
33. Shugarts S, Benet LZ,. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res, 2009; 26: 2039-2054.
34. Grover A, Benet LZ,. Effects of drug transporters on volume of distribution. AAPS PharmSci, 2009; 11: 250-261.
35. Hall RG, Leff RD, Gumbo T,. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2009; 29: 1468-1481.
36. Johnson DA, Smith KD,. The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein. Biomed Chromatogr, 2006; 20: 551-560. (Pubitemid 44043399)